SeaStar Medical to Present at Upcoming NobleCon21 Investor Conference

SeaStar Medical Holding Corporation (Nasdaq: ICU) has announced that CEO Eric Schlorff will present at the upcoming NobleCon21, the Twenty-First Annual Emerging Growth Equity Conference hosted by Noble Capital Markets. The event will take place on December 3, 2025, at Florida Atlantic University in Boca Raton, Florida. During his presentation, Schlorff aims to provide insights into the company's innovative approaches to treating critically ill patients facing organ failure. Investors and interested guests are invited to attend, with registration available using the code ICUNOBLECON.

SeaStar Medical, primarily focused on transforming the landscape of critical care medicine, has made substantial progress with its QUELIMMUNE (SCD-PED) therapy. This groundbreaking product, developed from the proprietary Selective Cytopheretic Device (SCD) technology, received FDA approval in 2024. It stands out as the only FDA-approved treatment targeting life-threatening acute kidney injury (AKI) due to sepsis in critically ill pediatric patients, marking a significant advancement in addressing this ultra-rare medical condition.

The company has also gained Breakthrough Device Designation from the FDA for six therapeutic indications, providing a favorable pathway for future approvals and reimbursement considerations. Currently, SeaStar Medical is conducting a pivotal trial of its SCD therapy for adult patients with AKI who require continuous renal replacement therapy (CRRT)—a serious health issue that affects over 200,000 adults in the U.S. annually and lacks effective treatment options.

A replay of Schlorff's presentation will be available on the company's website on December 4, 2025, for those unable to attend live. For further information, stakeholders are encouraged to visit SeaStar Medical's website or connect via LinkedIn and X.

SeaStar Medical Holding Corporation (Nasdaq: ICU) presents an intriguing investment opportunity ahead of its appearance at NobleCon21 on December 3, 2025. The company is centered on addressing acute kidney injury (AKI) through its innovative Selective Cytopheretic Device (SCD) technology and its FDA-approved QUELIMMUNE (SCD-PED) therapy for pediatric patients suffering from sepsis-related complications. This direct alignment with critical healthcare needs, coupled with the sole FDA approval for such a rare condition, positions SeaStar as a potential leader in its niche market.

Investors should keenly observe the upcoming presentation for insights on further developments regarding the pivotal trial of the SCD therapy in adults, which encompasses a significant patient population in the U.S. Given that over 200,000 adults face the challenges of AKI annually and currently lack effective treatment avenues, successful outcomes in this trial could catalyze substantial growth for SeaStar.

As investors, it is crucial to assess not just the technology's potential but also the company's strategic plans for commercialization. SeaStar's Breakthrough Device Designation from the FDA for multiple indications signifies favorable regulatory dynamics, which could translate to more efficient market accessibility and reimbursement pathways.

Market analysts suggest viewing the upcoming NobleCon presentation as a catalyst for reflecting on the company’s growth trajectory within the broader healthcare sector. Increased visibility and investor interest might unlock substantial opportunities, particularly if management outlines solid strategies for scaling operations and addressing investor concerns. Following the conference, the replay, accessible until January 3, 2026, will be essential for tracking any actionable insights that emerge from CEO Eric Schlorff’s dialogue. As SeaStar Medical continues to carve a niche in critical care solutions, it may represent a unique investment opportunity in an undercapitalized sector.